Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
E5TION will evaluate the efficacy, safety and tolerability of tailored two regimens
(prasugrel 5mg/d vs. ticagrelor 60mg bid) in high-risk patients undergoing PCI (CHIP: COmplex
and Higher-Risk Indicated PCI/PatieNts).